Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 2, 2016, Pages 1097-1105

  Ferro, Beatriz E ^a   Meletiadis, Joseph ^b,c   Wattenberg, Melanie ^a   De Jong, Arjan ^a   Van Soolingen, Dick ^a,d   Mouton, Johan W ^a,c   Van Ingen, Jakko ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CLARITHROMYCIN; CLOFAZIMINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM COLONY; CODON; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MONTE CARLO METHOD; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; NONHUMAN; PRIORITY JOURNAL; RESPONSE SURFACE METHOD; ATYPICAL MYCOBACTERIUM; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG INTERACTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MUTATION;

AMIKACIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; CLOFAZIMINE; DRUG INTERACTIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; MUTATION; MYCOBACTERIUM AVIUM; NONTUBERCULOUS MYCOBACTERIA;

EID: 84957922091     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02615-15     Document Type: Article

References (26)

1. van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boere MJ, Daley CL. 2012. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother 56:6324-6327. http://dx.doi.org/10.1128/AAC.01505-12.
2. van Ingen J, Ferro BE, Hoefsloot W, van Soolingen D. 2013. Drug treatment of pulmonary antituberculous mycobacterial disease in HIV-negative patients: the evidence. Expert Rev Anti Infect Ther 11:1065-1077. http://dx.doi.org/10.1586/14787210.2013.830413.
3. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburg R, Huitt G, Lademaco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Jr, Winthrop K, ATS Mycobacterial Diseases Subcommittee. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175:367-416. http://dx.doi.org/10.1164/rccm.200604-571ST.
4. Reddy VM, O'Sullivan JF, Gangadharam PR. 1999. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother 43:615-623.
5. Swanson RV, Adamson J, Moodley C, Ngcobo B, Ammerman NC, Dorasamy A, Moodley S, Mgaga Z, Tapley A, Bester LA, Singh S, Grosset JH, Almeida DV. 2015. Pharmacokinetics and pharmacodynamics of clofazimine in the mouse model of tuberculosis. Antimicrob Agents Chemother 59:3042-3305. http://dx.doi.org/10.1128/AAC.00260-15.
6. Shen GH, Wu BD, Hu ST, Lin CF, Wu KM, Chen JH. 2010. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 35:400-404. http://dx.doi.org/10.1016/j.ijantimicag.2009.12.008.
7. Fattorini L, Piersimoni C, Tortoli E, Xiao Y, Santoro C, Ricci ML, Orefici G. 1995. In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium. Antimicrob Agents Chemother 39:680-685. http://dx.doi.org/10.1128/AAC.39.3.680.
8. Meletiadis J, Petraitis V, Petraitiene R, Lin P, Stergiopoulou T, Kelaher AM, Sein T, Schaufele RL, Bacher J, Walsh TJ. 2006. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis 194:1008-1018. http://dx.doi.org/10.1086/506617.
9. Meletiadis J, te Dorsthorst DTA, Verweij PE. 2006. The concentration-dependent nature of the in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions. Int J Antimicrob Agents 28:439-449. http://dx.doi.org/10.1016/j.ijantimicag.2006.07.011.
10. Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of mycobacteria, Nocardia, and other aerobic actinomycetes; approved standard, 2nd ed. CLSI document M24-A2. CLSI, Wayne, PA.
11. Nessar R, Reyrat JM, Murray A, Gicquel B. 2011. Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus. J Antimicrob Chemother 66:1719-1724. http://dx.doi.org/10.1093/jac/dkr209.
12. Bastian S, Veziris N, Roux AL, Brossier F, Gaillard JL, Jarlier V, Cambau E. 2011. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 55:775-781. http://dx.doi.org/10.1128/AAC.00861-10.
13. van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB, Peloquin CA, Daley CL. 2012. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med 186:559-565. http://dx.doi.org/10.1164/rccm.201204-0682OC.
14. Tayman C, El-Attug MN, Adams E, van Schepdael A, Debeer A, Allegaert K, Smits A. 2011. Quantification of amikacin in bronchial epithelial lining fluid in neonates. Antimicrob Agents Chemother 55:3990-3993. http://dx.doi.org/10.1128/AAC.00277-11.
15. Ikawa K, Kikuchi E, Kikuchi J, Nishimura M, Derendorf H, Morikawa N. 2014. Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages. J Clin Pharm Ther 39:411-417. http://dx.doi.org/10.1111/jcpt.12157.
16. Ferro BE, van Ingen J, Wattenberg M, van Soolingen D, Mouton JW. 2015. Time-kill kinetics of antibiotics active against rapidly growing mycobacteria. J Antimicrob Chemother 70:811-817. http://dx.doi.org/10.1093/jac/dku431.
17. Ferro BE, van Ingen J, Wattenberg M, van Soolingen D, Mouton JW. 2015. Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease. J Antimicrob Chemother 70:2838-2843. http://dx.doi.org/10.1093/jac/dkv180.
18. Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R. 2012. Clofazimine: current status and future prospects. J Antimicrob Chemother 67:290-298. http://dx.doi.org/10.1093/jac/dkr444.
19. Field SK, Cowie RL. 2003. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol and clofazimine. Chest 124:1482-1486. http://dx.doi.org/10.1378/chest.124.4.1482.
20. Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. 2011. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 52:565-571. http://dx.doi.org/10.1093/cid/ciq237.
21. Burian J, Ramón-García S, Howes CG, Thompson CJ. 2012. WhiB7, a transcriptional activator that coordinates physiology with intrinsic drug resistance in Mycobacterium tuberculosis. Expert Rev Anti Infect Ther 10:1037-1047. http://dx.doi.org/10.1586/eri.12.90.
22. Schmalstieg AM, Srivastava S, Belkaya S, Deshpande D, Meek C, Leff R, van Oers NS, Gumbo T. 2012. The antibiotic resistance arrow of time: efflux pump induction is a first step in the evolution of mycobacterial drug resistance. Antimicrob Agents Chemother 56:4806-4815. http://dx.doi.org/10.1128/AAC.05546-11.
23. Olivier KN, Gupta R, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume P, Dorgan D, Salathe MA, Brown-Elliott BA, Wallace RJ, Griffith DE 2014. A randomized, double-blind, placebo-controlled study of liposomal amikacin for inhalation (Arikace®) in patients with recalcitrant nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med 189:A4126.
24. Drusano GL, Neely M, van Guilder M, Schumitzky A, Brown D, Fikes S, Peloquin C, Louie A. 2014. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. PLoS One 9:e101311. http://dx.doi.org/10.1371/journal.pone.0101311.
25. Chiodini RJ. 1991. Antimicrobial activity of rifabutin in combination with two and three other antimicrobial agents against strains of Mycobacterium paratuberculosis. J Antimicrob Chemother 27:171-176. http://dx.doi.org/10.1093/jac/27.2.171.
26. Kent RJ, Bakhtiar M, Shanson DC. 1992. The in-vitro bactericidal activities of combinations of antimicrobial agents against clinical isolates of Mycobacterium avium-intracellulare. J Antimicrob Chemother 30:643-650. http://dx.doi.org/10.1093/jac/30.5.643.